Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 20000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The business’s fifty day moving average is C$0.01 and its two-hundred day moving average is C$0.02. The stock has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- Micron Stock Under $100: Seize the AI-Driven Upside
- Using the MarketBeat Stock Split Calculator
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- ETF Screener: Uses and Step-by-Step Guide
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
